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THE nature of soluble factors that regulate fibroblast pro-
liferation have not been finally characterized. Our aim was
to study the role of tumour necrosis factor (TNF-z) and
interleukin-1 (IL-1) in the suppressive activity of alveolar
macrophages on autologous lung fibroblasts proliferation
in sarcoidosis. We found that supernatants recovered from
alveolar macrophages suppressed the proliferation of
alveolar fibroblast in sarcoidosis by 35.5 + 1.13% com-
pared to 3 + 16% in controls (p < 0.001 between the two
groups). This suppression correlated with high content of
TNF-ff and IL-1 in sarcoidosis patients stage II-III
(7.7 + 2.9 ng/ml TNF-and 157 + 53 U/ml IL-1 compared
to 3.4 + 2.4 ng/ml TNF- and 43 U/ml IL-1 in controls;
p < 0.01 and p < 0.001, respectively). Both cytokines in
sarcoidosis stage I were within the normal ranges.
Exogenous TNF- (1000-0.5 ng/ml) and IL-1 (500-0.24
ng/ml) had an additive suppressive activity on fibroblast
proliferation which was partially reversed by in-
domethacin.
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Introduction
The injury of any tissue, whether caused by
trauma, microbes or a foreign antigen, initiates any
inflammatory response which leads to the normal
physiological process of healing. Acute pneumo-
nias, even those with marked necrosis, can heal
without excessive scarring. In contrast, interstitial
disorders may result in excessive fibrosis with loss
of organ function. The processes responsible for
these different outcomes need further definition.
Mononuclear cells are important regulators of the
fibrotic response. Their regulatory effects are at least
partially mediated by soluble factors that can
stimulate1’2 or inhibit3’4 fibroblast proliferation.
Interleukin-1 (IL-1) protein has pronounced
effects on various lineages of cells and other cells
of mesenchymal origin, s’6 Stimulated monocytes
and macrophages also elaborate tumour necrosis
factor (TNF-o0 which is now known to have a
broad range of cytoregulatory effects7’8 including
the ability to regulate cell proliferation. Moreover
TNF-o and IL-1 synergistically stimulate PGE2
el6boration by confluent fibroblast. Because
mononuclear cell inflammation precedes the fibrotic
stage in sarcoidosis the cytokines released by
alveolar macrophages and their role on fibroblast
growth may have a crucial role. To test this theory
we determined the suppressive effect of alveolar
macrophage supernatants from patients with
sarcoidosis on proliferation of autologous alveolar
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fibroblasts and correlated it with their TNF- and
IL-1 content.
Materials and Methods
Study population: Patients were subdivided into three
groups. Sarcoidosis patients were diagnosed by
clinical and roentgenological presentation, a posi-
tive Kweim test or positive biopsy of non-caseating
granuloma. According to the X-rays these patients
were grouped into stage I (four untreated patients)
and stage 11-Ili (nine untreated patients). For
controls, seven untreated patients undergoing
bronchoscopy due to unexplained persistent cough
or after an episode of mild haemoptysis. All of them
had chest roentgenograms within normal limits.
Written informed consent was obtained from each
subject before bronchoscopy and bronchoalveolar
lavage.
Bronchoalveolar lavage: After informed consent, bron-
choscopy with bronchoalveolar lavage was per-
formed with a flexible fibre optic bronchoscope
(Olympus BF-B2) as previously described.1
Preparation of alveolar macrophages: The recovered fluid
was collected in specimen traps, filtered through
sterile gauze and centrifuged at 400 x g for 15 min
at 4C. The pellet obtained was washed three times
with cold PBS (Biological Industries, Beit Haemek),
the number of viable cells was counted and purified
by adherence as previously described.
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Preparation oflungflbroblasts: Alveolar fibroblasts (Afb)
were obtained from bronchoalveolar lavage cells
after long-term incubation (3-4 weeks) as previous-
ly described. 11 Control fibroblasts were derived
from histologically normal areas of lungs resected
for diagnostic reasons. The techniques of prepara-
tion and the proliferative characteristics of these
cells have been described.
12
Preparation of alveolar macrophage supernatants: Super-
natants were obtained from alveolar cells cultured
as previously described. The cells were allowed to
adhere for 1 h, washed vigorously and overlayed by
an identical volume of complete RPMI medium (2%
foetal calf serum (FCS), antibiotic-antimycotic)
with or without 10 #g/ml lipopolysaccharide (LPS)
(Difco, St Louis, USA 055:B55). The cells were
incubated for 24 h in 5% CO2. Aliquots of the
medium harvested from cultures were centrifuged,
filtered and frozen for future use at -70C.
Fibroblast proliferation test: Fibroblast suspension
(100/d) was recovered as described previously.
Briefly, cells were washed and resuspended in
Dulbecco modified Eagles medium (DMEM) with
1% FCS, 2-mercaptoethanol (5 x 10-5 M) and 1%
antibiotic-antimycotic mixture at 105 cells/ml.
Fibroblasts were dispensed into each well of 96-well
flat-bottomed microtitre plates and allowed to
attach for 1-2 h. Aliquots (100/d) of supernatants
of LPS pulsed alveolar macrophages were added.
Cultures were incubated in a humidified 5% COg
atmosphere for 72 h, and pulsed with 1 Ci3H
thymidine for the last 4h of culture. For
harvesting, the supernatant from each well was
aspirated and 0.1 ml trypsin-EDTA was added to
each well. Detached cells were harvested and
counted. The growth of fibroblasts in LPS
stimulated alveolar macrophage supernatant or
cytokines (rlL-1 500-0.24 ng/ml Glaxo IMB;
TNF- 1000-0.5 ng/ml Genentech Inc, San
Francisco, CA, USA) was compared with the
growth of fibroblasts in complete DMEM with and
without a final concentration of 10/,g/ml LPS.
Neutralization ofTNF- and IL-1 activity was done
by anti-TNF and anti-IL-1 MoAbs (240 #g/ml,
Genentech and 20/.tg/ml, Genzime respectively)
and PGE2 was reversed by indomethacin (1/g/ml,
Sigma, Chemical Co, St Louis Mo, USA).
Assay of prostaglandin, TNF and IL-1 production:
Aliquots of alveolar macrophage supernatants (24 h
production) were assayed for PGE2 and IL-1
production. PGE2 was assayed using an ELISA kit
(Advanced Magnetic Inc.), TNF- was measured
by a biological assay on A9 target cells, and IL-1
by the C3H/HeJ thymocyte comitogenic assay, as
described previously.
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Table 1. TNF-, IL-1 and PGE2 mean contents of alveolar
macrophage supernatants*
Diagnosis TNF- (ng/ml) IL-1 (U/ml) PGE2 (ng/ml)
Stage (4) 1.1 +__ 0.8 42 +_ 35 0.13 + 0.05
Stage 11-111(9) **7.7 __+ 2.9 +157 -I- 33 + +0.45 -I- 0.28
Control (7) 3.4 -I- 2.4 43 -!- 26 0.34 ___
0.2
^No. of cases.
* TNF and L-1 were measured by biological methods in 24 h
supernatants of six stimulated alveolar macrophages. PGE2
was measured by an ELISA assay in 72 h supernatants of six
stimulated alveolar macrophages.
** p < 0.01 compared to controls.
+ p < 0.001 compared to controls.
++ p < 0.001 compared to stage sarcoidosis; no significant
differences between PG E2.
Content of sarcoidosis stage I1-111 and control group.
Results
The content of TNF-, IL-1 and PGE2 in
alveolar macrophage supernatants in all patients
tested is shown in Table 1. No differences were
observed in the secretion of the compounds
between sarcoidosis stage I and the control group.
A high secretion of IL-1 and TNF- not correlated
to increase in secretion of PGE2 is seen in
supernatants of sarcoidosis patients stage II-III.
The effects of these supernatants were tested on the
proliferation of alveolar fibroblasts (Table 2).
Alveolar macrophage supernatants from sarcoidosis
patients suppressed the proliferation of alveolar
fibroblasts by 38___ 7.13% whereas alveolar
macrophage supernatants from controls induced
only a slight suppression of 3 ___
16% < 0.01
between sarcoidosis patients and controls).
The suppressive activity of alveolar macrophages
from stage II-III sarcoidosis patients was correlated
with a marked increase in secretion of IL-1 and
TNF-. In view of this fact we determined if
exogenous cell-free rTNF- and IL-1 have sup-
pressive effects on fibroblasts. As shown in Table
3 and Fig. 1 both IL-1 and TNF- suppressed
fibroblast proliferation. The suppressive effect of
IL-1 was reversed by indomethacin (Table 3). The
specificity of suppressive activity of TNF- and
IL-1 was ascertained by neutralization with
anti-TNF- and anti-IL-1 mAbs (Table 3).
Concomitant addition of IL-1 and TNF- resulted
in an additive suppressive effect (Fig. 2) which was
also partially reversed by indomethacin.
Discussion
The cells involved in the inflammatory response
generate a variety of factors which appear to
regulate the healing process through the recruit-
ment, stimulation of growth, and matrix synthesis
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Table 2. Effect of alveolar macrophage supernatants on alveolar fibroblast proliferation
+Medium Proliferation of sarcoid alveolar fibroblasts*
+ Sup. of sarcoidosis
alveolar macrophages
% Supp/enhan.+ + Sup. of control
alveolar macrophages
% Supp/enhan.+ +
7753 + 1007 4940 -I- 506 37 7001 + 805 10
9399 + 297 5442 + 516 42 12213 _+ 1462 29
1801 + 1007 921 + 60 49 1441 +__ 210 20
7613 + 1007 4971 -I- 1661 35 8153 _+ 574 7
6047 + 268 4507 + 315 26 5630 + 162 7
2633 ___
853 1528 + 113 42 2200 -I- 193 13
* One hundred /A of autologous alveolar fibroblasts at a final concentration of 10s cell/ml were incubated in 96-well
microplates with or without AM supernatants for 72 h. For the last 4 h cells were pulsed with 0.1 /Ci[3H]-thymidine.
/ Mean suppression by sarcoidosis alveolar macrophages supernatants 38.5 ___
7.13%.
/ / Mean suppression by control alveolar macrophages supernatants. 3 -I- 16%. p < 0.001 between two groups.
+ means suppression; means enhancement.
Table 3. Effect of indomethacin and MoAbs to the induced
L-1 and TNF depression on fibroblast proliferation*
Sarcoidosis Controls
Medium 4778 __+ 235 54173 __+ 1327
IL-1
/ 3561 __+ 607 47808 + 1866
IL-1 + Ind
/ / 7516 -I- 354 48977 __+ 9649
IL-1 + mAbs 5508 __+ 142 46689 ___
780
Medium 9968 + 292 60069 +__ 28
TNF
/ 6704 _+ 1486 22134 + 853
TNF + Ind
+/ 5520 __+ 1577 31018 __+ 2006
TNF + mAbs 18714 __+ 3145 44152 -I- 1530
* cpm of 3[H]-thymidine incorporation of fibroblasts.
/ IL-1 15 ng/ml; TNF 10 ng/ml.
/ / Indomethacin #g/ml.
^mAbs IL-1 20/g/ml; mAbs TNF 240/g/ml.
by connective tissue cells. 14 Accumulating evidence
indicates that monocyte-macrophage products play
an important role in modulating connective tissue
alteration in inflammatory diseases, is Recent studies
have focused on the role of IL-1, TNF-o, IFN’c,
16-18
IL-619 and PGE22 in the regulation of fibroblast
growth and function in the normal lung but little
O
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FIG. 1. Effect of IL-1 and TNF-= on fibroblast proliferation. Combined
rlL-1 in serial dilutions of 500-0.24 ng/ml and TNF-= in serial dilutions of
1000-0.5 ng/ml were added to control fibroblasts at a final concentration
of 10 cells/ml for 72 h. During the last 4 h cells were pulsed with #Ci
[3H]-thymidine and incorporation was expressed in counts per minute
(cpm). p < 0.01 between baseline of fibroblasts and after addition ofTNF
(1:128), and p<0.001 after addition of TNF and IL-I. --A
IL-1 +TNF-; mC)--, IL-1 +TNF-=+ IND.
is known about the role of these factors in
interstitial lung diseases.
To understand further the role of these factors
we characterized the effect of alveolar macrophage
supernatants from patients with sarcoidosis on
alveolar fibroblast proliferation and compared it
with the control group. The experiments showed
that sarcoidosis supernatants exerted an inhibitory
effect whereas the control supernatants induced
only a slight suppression or enhancement. These
results confirmed those previously shown21 but they
reflect more closely the in vivo situation as each
alveolar macrophage supernatant was incubated
with the autologous fibroblasts.
Although previous studies showed already that
alveolar macrophages from sarcoidosis patients
secrete increased amounts of IL-122 and TNF-0,
2
the importance of the intercytokine interactions in
correlation with different staging in sarcoidosis has
not been investigated adequately. We demonstrate
here that alveolar macrophages secrete high
amounts of TNF and IL-1 and also exhibit marked
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FIG. 2. Effect of indomethacin on the TNF-= and IL-1 induced
suppression of fibroblasts. Proliferation of control fibroblasts was tested
in the presence of TNF-= and IL-1 with and without #g/ml
indomethacin. During the last 4 h cells were pulsed with #Ci[3H]
thymidine and incorporation was expressed in counts per minute
(cpm). p < 0.001 between fibroblast proliferation with TNF-0 and IL-1
(1:128) before and after addition of indomethacin, qAm, IL-1 +TNF-=;
ml-"l TNF-z;qm, IL-1.
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suppressive activity of fibroblast proliferation only
in patients with stage II-III sarcoidosis. The high
secretion of TNF-o and 1L-1 was not correlated to
similar increases in PGE2 secretion. It should be
noted that down-regulation of PGE2 secretion by
alveolar macrophages from sarcoidosis patients has
been reported already.
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The high secretion of both cytokines seems to
have a definitive suppressive role as the exogenous
addition ofTNF- and IL-1 have a net suppressive
effect on fibroblast proliferation within the range
secreted by alveolar macrophages in sarcoidosis
patients (1-10 ng/ml for TNF and 100-500 U/ml for
IL-1).
Sarcoidosis is a multi-system granulornatous
disease with a benign clinical course in the majority
of the patients. The disease progresses from
granulomatous inflammation to fibrosis only in
about 10-20% of cases.25’26 It is possible that the
high secretion of TNF-o and IL-1 is involved in
limiting the fibrotic response. In stage I-II
sarcoidosis we showed high secretion of IL-1 only,
which can have simultaneously stimulatory and
inhibitory effects on fibroblast proliferation as
already reported for osteoclasts.27 It is of interest
that indomethacin partially reversed the suppressive
effect of TNF- and IL-1. Apparently this effect is
not due to the well-known property of in-
domethacin as a cyclooxygenase inhibitor but may
reflect a direct effect of cytokines.
These studies show that cytokines can have
multiple effects on fibroblast proliferation and that
the effect that is noted depends on the entire set of
regulatory factors affecting the target cell.
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